Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant

Inclusion Criteria: * Male or female patients ages \> 18 yrs * Patients undergoing high dose chemotherapy with or without radiation therapy treatment as conditioning for autologous hematopoietic stem cell transplantation. The conditioning regimens include at least one of the following: high dose melphalan (Mel 200), busulfan, or etoposide, with or without total body irradiation. * Patients with Karnofsky performance scores \> or = 70% * Informed consent for participation in study Exclusion Criteria: * Patients who weigh \< 33 kg * Premenopausal female patients who are pregnant, lactating or are likely to become pregnant * Patients with active medical conditions that preclude autologous hematopoietic stem cell transplantation * Patients diagnosed with active acquired immunodeficiency syndrome (AIDS) or Hepatitis B/C * Patients with known hypersensitivity to recombinant protein therapeutics * Patients who have taken CG53135-05, palifermin or other investigational drugs in the past 30 days * Patients who have untreated symptomatic dental infection * Patients with a history of sensitivity or allergy to E. coli-derived products * Patients with WHO Grade 3 or 4 oral mucositis (OM)